About 5 results found for searched term "77-38-3" (0.12 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M5514 | Chlorphenoxamine | Histamine Receptor |
| Chlorphenoxamine is an antihistamine and anticholinergic used as an antipruritic and antiparkinsonian agent. | ||
| M20777 | GSK5182 | Estrogen Receptor |
| GSK5182 is a 4-Hydroxytamoxifen analog and a highly potent, selective, orally active estrogen-related receptor gamma (ERRγ) inverse agonist with an IC50 value of 79 nM.GSK5182 does not interact with other nuclear receptors, including ERRα and ERα. In addition, GSK5182 inhibits proinflammatory cytokine-induced catabolic factors and increases ROS production in liver cancer cells. cytokine-induced catabolic factors and increased ROS production in hepatocellular carcinoma cells. | ||
| M5327 | L-779450 | Raf |
| L-779450 is a potent, ATP-competitive Raf kinase inhibitor (IC50 =10 nM) that displays > 7, > 30 and > 70-fold selectivity over p38α, GSK3β and Lck respectively. | ||
| M11405 | Inavolisib (GDC-0077) | PI3K |
| GDC-0077; RG6114；RO-7113755 | ||
| Inavolisib (GDC-0077; RG6114) is a potential best-in-class, orally selective PI3Kα inhibitor (IC50=0.038 nM). GDC-0077 (RG6114) exerts its activity by binding to the ATP binding site of PI3K, thereby inhibiting the phosphorylation of PIP2 to PIP3. GDC-0077 (RG6114) is more selective for mutants compared to wild-type PI3Kα. It can trigger the degradation of mutation-producing PIK3α. | ||
| M29645 | MSC-4381 | Monocarboxylate Transporter (MCT) |
| MCT4-IN-1 | ||
| MSC-4381 (MCT4-IN-1) is an orally active and selective monocarboxylate transporter 4 (MCT4/SLC16A3) inhibitor with an IC50 of 77 nM and a Ki of 11 nM. MSC-4381 targets to the cytosolic domain of MCT4. MSC-4381 results in lactate efflux inhibition and reduction of cellular viability in MCT4 high expressing cells. MSC-4381 has the potential for MCT4 transporter inhibition research. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
